Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
4
×
life sciences
national blog main
national top stories
indiana blog main
indiana top stories
san francisco blog main
san francisco top stories
boston
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe blog main
europe top stories
m&a
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
2019
activism
acute hepatic porphyria
aimmune therapeutics
allergy
alnylam pharmaceuticals
anaphylaxis
andrew oxtoby
avapritinib
What
approval
4
×
therapy
4
×
drug
fda
gene
therapeutics
treat
won
address
advanced
agency
aimmune
allergy
alnylam’s
approved
approves
awarded
betting
bff
billion
bio
biopharma
blueprint
cancer
carries
certain
conference
deal
deals
designed
developed
devoted
disease
duchenne
easl
form
friday
genetic
historic
immunotherapy
Language
unset
Current search:
therapy
×
approval
×
" boston top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More